Moody's Downgrades Valeant Pharma (VRX) CFR to B3 from B2; Outlook Negative
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Reports Third Quarter 2016 Financial Results
November 8, 2016 6:00 AM EST- Total Revenues of $2.48 billion
- GAAP Cash Flow from Operations of $570 million
- GAAP EPS of ($3.49) and Adjusted EPS (non-GAAP) of $1.55
- Revising 2016 Full Year Guidance
LAVAL, Quebec, Nov. 8, 2016 /PRNewswire/ --Â Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced third quarter 2016 financial results.
"This past quarter, we made further progress toward establishing the new Valeant," said Joseph C. Papa, Chairman and Chief Executive Officer. "We have, where... More
